A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
Keep Reading →
August 26 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
August 26 - News
Since the first day of the week can predict the flow of the whole week, it is particularly crucial to focus on Monday news and events.
Keep Reading →
August 26 - News
Every investor has heard the old line "sell in May and go away." That wasn't such great advice this year with the S&P 500 index up nearly 5% since the beginning of May.
Keep Reading →
August 26 - News
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 25 - News
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
Keep Reading →
August 24 - News
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Keep Reading →
August 23 - News
There's been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN).
Keep Reading →
August 23 - News
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. ...VIVUS, Inc.
Keep Reading →
August 22 - News
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
August 22 - News
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Keep Reading →
August 21 - News
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Keep Reading →
August 21 - News
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Keep Reading →
August 21 - News
The ratings of four Pharmaceutical stocks are down this week, according to the Portfolio Grader database.
Keep Reading →
August 19 - News
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Keep Reading →
August 19 - News
Earlier today RFD IP Business Services ("RFD") released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc.
Keep Reading →
August 13 - News
Dividend investors would be wise to focus not just on a stock's current yield, but also on the long-term growth potential of its dividends.
Keep Reading →
August 12 - News
Baseball star Alex Rodriguez had an opportunity to be perhaps the greatest player of the past decade or even longer -- that was until he threw it all away by admitting to steroid...
Keep Reading →
August 10 - News
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc.
Keep Reading →
August 7 - News
The Motley Fool's readers have spoken, and I have heeded their cries.
Keep Reading →
August 7 - News
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
Keep Reading →
August 6 - News
Vical Incorporated (NASDAQ:VICL) announced its second-quarter results on Thursday.
Keep Reading →
August 2 - News
It isn't very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that's exactly where the Food and Drug Administration...
Keep Reading →
August 2 - News
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Keep Reading →
August 1 - News
Merck & Co., Inc. (NYSE:MRK) might be one of big pharma's largest companies, but this health care leader has had a tough go recently.
Keep Reading →
July 31 - News
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO.
Keep Reading →
July 30 - News
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
July 26 - News
Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered...
Keep Reading →
July 25 - News
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Keep Reading →
July 24 - News
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Keep Reading →
July 24 - News
We have a bona fide biotech soap opera going on these days. Spurned love. Possible romance. Disgruntled suitor. And, of course, the unknown villain.
Keep Reading →
July 24 - News
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Keep Reading →
July 22 - News
Times have changed, and women are stepping in to close the gender gap in corporate America.
Keep Reading →
July 22 - News
In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health.
Keep Reading →
July 19 - News
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Keep Reading →
July 19 - News
The Food and Drug Administration cancelled an advisory meeting planned for Merck & Co., Inc. (NYSE:MRK)’s post-surgery drug sugammadex.
Keep Reading →
July 19 - News
The story of the second quarter for Novartis AG (ADR) (NYSE:NVS) offered mixed results for investors. The company's net sales were up 1%, and EPS was down 6% year over year.
Keep Reading →
July 18 - News
Chances are that a few biotech companies will be scooped up by larger players over the coming months.
Keep Reading →
July 17 - News
Arthritis biologics like Remicade, Enbrel, and Humira are pricy drugs that many of the 50 million American arthritis patients – and hundreds of millions of patients worldwide...
Keep Reading →
July 16 - News
Cancer-drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen, Inc. (NASDAQ:AMGN).
Keep Reading →
July 10 - News
Pharma companies have been paying off generic drug makers so that cheap generic drugs do not enter the market. In a settlement case involving AbbVie Inc (NYSE:ABBV), the U.S.
Keep Reading →
July 9 - News
Several companies are fighting to be the first to release a treatment or cure for cancer that is a game-changer, and this battle has created a field where firms are looking to...
Keep Reading →
July 8 - News
While many American skies were lit up with fireworks this week, the stock market also saw its share of pops, sizzles, and bangs.
Keep Reading →
July 8 - News
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
Keep Reading →
July 5 - News
This year, the North American players in the biotechnology industry are expected to spend $15 billion.
Keep Reading →
July 5 - News
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) has recently experienced a significant jump of nearly 51.3% in only one trading day from $86.82 per share to $131.30 per share.
Keep Reading →
July 5 - News
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Keep Reading →
July 5 - News
For the second day in a row, the hot topic in the market is the bidding war for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX). After rejecting Amgen, Inc.
Keep Reading →
July 3 - News
